Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i> -ITD Mutant/ <i>TP53</i> Wild-type Acute Myeloid Leukemias
Preclinical and mechanistic rationale and preliminary clinical data support the future development of MDM2/FLT3-targeting strategies for FLT3-mutant AML.
Authors
- Nikolai Alexandrovich Podoltsev (ORCID: https://orcid.org/0000-0002-3657-778X)
- Muharrem Müftüoğlu (ORCID: https://orcid.org/0000-0001-8100-8554)
- Arnaud Lesegretain (ORCID: https://orcid.org/0000-0003-3732-1273)
- Fumie Tanzawa
- Weiguo Zhang (ORCID: https://orcid.org/0000-0002-3294-6322)
- Naval Guastad Daver (ORCID: https://orcid.org/0000-0001-7103-373X)
- Gary J. Schiller (ORCID: https://orcid.org/0000-0002-7508-3467)
- Koichi Iwanaga
- Harry Paul Erba (ORCID: https://orcid.org/0000-0003-1093-2189)
- Mahesh Basyal
- Takahiko Seki (ORCID: https://orcid.org/0000-0002-1531-3291)
- Michael Andreeff (ORCID: https://orcid.org/0000-0002-1144-1958)
- Prasanna Kumar (ORCID: https://orcid.org/0009-0007-1789-5057)
- Li Li (ORCID: https://orcid.org/0000-0002-6680-5886)
- Noriko Togashi (ORCID: https://orcid.org/0000-0003-2606-0231)
- Dale L. Bixby (ORCID: https://orcid.org/0000-0001-6885-8239)
- Masashi Numata
- Takeshi Isoyama
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Duke University (US)
- Daiichi Sankyo (Germany) (DE)
- University of Michigan (US)
- Yale University (US)
- Daiichi-Sankyo (Japan) (JP)
- Duke Medical Center (US)
- Daiichi Sankyo (United States) (US)
- U-M Rogel Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2764
- Citations
- 4
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 7.08
Funders
- Daiichi Sankyo Company